Picture of Kalvista Pharmaceuticals logo

KALV — Kalvista Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapMomentum Trap

Kalvista Pharmaceuticals Inc reports results for the quarter ended in October - Earnings Summary

* Kalvista Pharmaceuticals Inc  KALV.OQ  reported a
quarterly
adjusted loss of 80 cents​​ per share for the quarter ended in
October, higher than the same quarter last year, when the
company reported EPS of -90 cents.  The mean expectation of
five analysts for the quarter was for a loss of 79 cents per
share. Wall Street expected results to range from -92 cents
to -66 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kalvista Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 80 cents​.
    * The company reported a quarterly loss of $27.65 million.
    * Kalvista Pharmaceuticals Inc shares had fallen by 6.9%
this
quarter and gained 32.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is  "buy."

Wall Street's median 12-month price target for Kalvista
Pharmaceuticals Inc is $20.00 
This summary was machine generated from LSEG data December 7 at
12:45 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Oct. 31 2023      -0.79          -0.80          Missed
 Jul. 31 2023      -0.86          -0.74          Beat
 Apr. 30 2023      -0.94          -0.77          Beat
 Jan. 31 2023      -0.98          -0.75          Beat

Recent news on Kalvista Pharmaceuticals

See all news